Here are Insider's biggest healthcare stories for November

Hello,

Welcome to a special Black Friday edition of Insider Healthcare! I'm healthcare editor Leah Rosenbaum, bringing you some of our favorite stories from November:

• A rushed Teladoc and Livongo merger led to a wave of senior exits;
• Getting patents could make or break psychedelic companies;
• One of Moderna's top scientists on why he thinks gene editing is the future of the company.

Comments, tips? Email me at lrosenbaum@insider.com or tweet @leah_rosenbaum. Let's get to it...

---

Sign up today and become an Insider for our lowest annual subscription rate ever — just $38 for full access to everything we offer.

---

Teladoc acquired Livongo to recreate healthcare. A rushed union, a wave of senior exits, and sky-high expectations are testing the $14 billion bet.

• It's been one year since Teladoc's megamerger with the chronic-care company Livongo.
• The goal is to build one app that covers primary care, chronic care, and other services.
• Teladoc has faced internal and external pressure, and more than 110 Livongo employees have left.

See the Insider scoop>>

---

The future of the psychedelics industry hinges on patents. Whoever wins could make billions.

• The nascent psychedelics industry is headed toward a reckoning.
• Experts say a slew of patent disclosures could determine the winners and losers of the space.
• That may also set off a wave of M&A as companies vie to win market share.

Check it out>>

---

The scientist who helped Moderna become a vaccine powerhouse tells us why he thinks gene editing is the future for the $91 billion biotech

• Eric Huang, who persuaded Moderna to make vaccines, is now steering the biotech into gene editing.
• Huang is the chief scientific officer of Moderna Genomics, a new unit in the $91 billion company.
• Huang intends to strike deals with smaller biotechs while building up Moderna's internal research.

Dive in>>

---

In case you missed it:

• How Amy Abernethy is rejiggering one of Verily's biggest bets to change clinical research and propel the Google spin-off into the future
• See the 16-slide presentation a former Uber exec used to raise $25 million to tackle the growing in-home care market
• The health-insurance giant UnitedHealth is sending more members to in-house doctors in a bid to lower costs and increase profits
• Cathie Wood's Ark has scooped up shares of Ginkgo and Zymergen as their stocks fell. Here's why she's betting synthetic biology will be the next wave of drug development.

---

-Leah